Aug 19, 2026
In this episode, rheumatologist and clinician-scientist Dr. Vinod Chandran discusses his research into a diagnostic test for psoriatic arthritis with NPF CSMO Dr. Guy Eakin.
Key learnings:
Early diagnosis of psoriatic arthritis (PsA) is critical
for better outcomes.
PsA is often difficult to recognize because symptoms vary widely
and can resemble common age-related joint or back pain. Earlier
identification and treatment can reduce joint damage, improve
quality of life, lower chronic pain burden, and potentially
decrease cardiovascular and mental health complications.
The heterogeneity of PsA makes developing a diagnostic
test especially challenging.
PsA presents differently across patients, sexes, ethnic groups, and
stages of disease. Some patients develop arthritis after psoriasis,
while others may develop it before or even without obvious
psoriasis, making a single broadly applicable diagnostic test
difficult to create.
A multi-omic approach shows promise for distinguishing
PsA from psoriasis alone.
Dr. Chandran's team evaluated multiple biological data sources,
including gene expression, microRNAs, proteins, and metabolites.
Their research identified a signature of approximately 200 markers
that could differentiate patients with PsA from those with
psoriasis only, demonstrating the feasibility of a biomarker-based
diagnostic test.
The future of precision medicine in psoriatic disease
depends on reliable biomarkers.
Beyond diagnosis, biomarkers could help predict disease severity,
guide treatment selection, and improve long-term outcomes by
identifying the right therapy for the right patient at the right
time. Achieving this will require continued collaboration,
validation across diverse populations, and development of
clinically practical, cost-effective tests.
Looking for more information related to his research? Read more about the NPF PsA Diagnostic Test Grant outcomes: https://www.psoriasis.org/advance/psoriatic-arthritis-diagnostic-test-grant/
This publication is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $375,000 with 100 percent funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.